View : 157 Download: 0
Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study
- Title
- Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study
- Authors
- Ogawa; Eiichi; Jun; Dae Won; Toyoda; Hidenori; Hsu; Yao-Chun; Yoon; Eileen L.; Ahn; Sang Bong; Yeh; Ming-Lun; Do; Son; Trinh; Huy N.; Takahashi; Hirokazu; Enomoto; Masaru; Kawada; Norifumi; Yasuda; Satoshi; Tseng; Cheng-Hao; Kawashima; Keigo; Lee; Han Ah; Inoue; Kaori; Haga; Hiroaki; Ai-Thien; Maeda; Mayumi; Hoang; Joseph H.; Cheung; Ramsey; Ueno; Yoshiyuki; Eguchi; Yuichiro; Furusyo; Norihiro; Yu; Ming-Lung; Tanaka; Yasuhito; Nguyen; Mindie H.
- Ewha Authors
- 이한아
- SCOPUS Author ID
- 이한아
- Issue Date
- 2024
- Journal Title
- Alimentary Pharmacology and Therapeutics
- ISSN
- 0269-2813
- Citation
- Alimentary Pharmacology and Therapeutics vol. 59, no. 2, pp. 239 - 248
- Keywords
- bone density; entecavir; hepatitis B virus; sequential therapy; tenofovir alafenamide
- Publisher
- John Wiley and Sons Inc
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited. Aims: To assess the treatment and renal/bone safety outcomes following the switch to TAF. Methods: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T-scores (L-spine) by bone absorptiometry by 24 months after switch to TAF. Results: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T-score improved significantly from −1.43 ± 1.36 to −1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9–89.5 ± 16.3 mL/min/1.73 m2, p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T-score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T-score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019). Conclusions: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable. © 2023 John Wiley & Sons Ltd.
- DOI
- 10.1111/apt.17785
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML